Stocktoria
Eloxx Pharmaceuticals, Inc. ELOX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2012-11-23
Eloxx Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $6.4M | $0 | — | — |
| Operating income | -$6.4M | -$2.5M | -$17.3M | -$34.4M | -$66.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.0M | -$3.1M | -$17.1M | -$36.1M | -$66.7M |
| EPS (diluted) | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 |
| Operating cash flow | -$6.3M | -$4.7M | -$14.3M | -$31.8M | -$35.0M |
| Free cash flow | — | — | — | -$31.9M | -$35.1M |
| Cash & equivalents | $4.8M | $111,000 | $1.1M | $19.2M | $42.3M |
| Total assets | $5.3M | $3.0M | $1.7M | $21.1M | $45.1M |
| Total liabilities | $17.2M | $27.3M | $24.3M | $31.8M | $22.8M |
| Shareholders' equity | -$11.9M | -$24.3M | -$22.6M | -$10.7M | $22.4M |
Source: SEC EDGAR filings · CIK 0001035354 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.